POZEN to Present at the Baird 2007 Growth Stock Conference

Business Wire, May 1, 2007

CHAPEL HILL, N.C. -- POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will present at the Robert W. Baird & Co. 2007 Growth Stock Conference on Thursday, May 10, 2007 at 7:45 a.m. (CT) at the Four Seasons Hotel in Chicago. Dr. Plachetka's presentation will be webcast and archived on POZEN's home page at www.pozen.com.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Trexima[TM] combining sumatriptan, formulated with RT Technology[TM], and naproxen sodium in a single tablet for the acute treatment of migraine, which is currently under review by the United States Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.